Objective: To describe characteristics of children with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA) who were enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry.
Methods: All children with ERA and those with juvenile PsA were identified. Demographic characteristics, clinical characteristics, and treatments were described. The children with sacroiliitis and those without sacroiliitis were compared. In the children with sacroiliitis, the first visit with clinically active sacroiliitis (which came first in 72% of cases) was compared to the first visit without clinically active sacroiliitis.
Results: A total of 902 children with ERA or juvenile PsA were identified. Children with ERA were older at diagnosis (ages 10.8 years versus 8.2 years; P < 0.01) and were more likely to be male (56% versus 38%; P < 0.01). Polyarticular involvement was reported in 57% of children with ERA and in 72% of those with juvenile PsA. Of the children tested, HLA-B27 was positive in 38% of those in the ERA group and in 12% of those in the juvenile PsA group. At least 1 biologic was taken by 72% of those with ERA and 64% of those with juvenile PsA. Sacroiliitis (diagnosed clinically and/or by imaging) was reported in 28% of the children (40% of those with ERA and 12% of those with juvenile PsA). Of these, 54% of the children were female, 36% were HLA-B27 positive, and 81% took at least 1 biologic. In children with sacroiliitis, scores according to the physician global assessment of disease activity, parent/patient global assessment of well-being, and clinical Juvenile Arthritis Disease Activity Score 10 were all significantly worse at the first visit with clinically active sacroiliitis versus the first visit without active sacroiliitis.
Conclusion: In this registry, there are more than 900 children with ERA or juvenile PsA. There was high biologic use in this population, especially in those with sacroiliitis. Further, there was equal sex representation in those children with sacroiliitis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/acr.24537 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Where are we in targeting hypoxia-induced pathways in inflammatory arthritis? Current understanding, insights, and future directions.
Int Immunopharmacol
January 2025
Department of Medicine, Division of Rheumatology, Queen's University, Kingston, Ontario, Canada; Faculty of Health Sciences, School of Medicine, Queen's University, Kingston, Ontario, Canada; Translational Institute of Medicine, Department of Medicine, Queen's University, Ontario, Canada; Rheumatology Clinic, Kingston Health Science Centre, Kingston, Ontario, Canada. Electronic address:
Introduction: Joint tissues affected by inflammatory arthritis (IA) create hypoxic microenvironments that sustain the inflammatory response. Although targeting molecules in hypoxia-induced pathways has provided valuable insights into potential novel therapies for various types of IA, progress remains preclinical, and no clinical trials have been conducted for IA.
Methods: A literature search was conducted to create a narrative review exploring the role of hypoxia and its signaling pathways in IA pathogenesis, as well as the potential and future directions for IA therapies that target hypoxia-induced molecules before moving forward to clinical applications.
Characteristics That Predict Psoriatic Arthritis by the Classification Criteria for Psoriatic Arthritis in Patients With Juvenile Idiopathic Arthritis 18 Years After Disease Onset.
ACR Open Rheumatol
January 2025
Uppsala University, Uppsala, Sweden.
Article Synopsis
- The study aimed to evaluate patients with juvenile idiopathic arthritis (JIA) to see how many fit the criteria for psoriatic arthritis (PsA) 18 years after the disease began.
- Of the 510 initially enrolled patients, only 434 participated in follow-up, with 9.4% meeting the CASPAR criteria for PsA, indicating CASPAR may be more effective in identifying these patients than the ILAR criteria.
- Key predictors for developing PsA included specific joint involvement at disease onset and the presence of psoriasis, nail abnormalities, or dactylitis, with dactylitis being the strongest predictor.
Serum selenium, selenoprotein P and glutathione peroxidase 3 in rheumatoid, psoriatic, juvenile idiopathic arthritis, and osteoarthritis.
J Nutr Biochem
January 2025
MVZ Endokrinologikum Berlin am Gendarmenmarkt, Berlin, Germany; Charité Universitätsmedizin Berlin, Klinik für Rheumatologie und Klinische Immunologie, Berlin, Germany. Electronic address:
Article Synopsis
- Selenoprotein P (SELENOP) and glutathione peroxidase 3 (GPx3) are vital for selenium transport and antioxidant activity in blood, with a focus on their roles in inflammatory rheumatic diseases like rheumatoid arthritis (RA), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA).
- A study involving 272 patients found that both SELENOP and selenium levels were lower in patients with inflammatory rheumatic diseases compared to healthy controls, with particularly low GPx3 activity in JIA and PsA groups.
- The findings suggest that selenoprotein deficiencies may contribute to disease severity, emphasizing the potential for personalized selenium supplementation to enhance selenoprotein production and improve
Extrapolation of Upadacitinib Efficacy in Juvenile Idiopathic Arthritis Leveraging Pharmacokinetics, Exposure-Response Models, and Real-World Patient Data.
Clin Pharmacol Ther
December 2024
Clinical Pharmacology, AbbVie Inc., North Chicago, Illinois, USA.
Juvenile idiopathic arthritis (JIA) is the most prevalent pediatric rheumatic disease. While disease-modifying antirheumatic drugs (DMARDs), especially biologics, have greatly transformed the management of JIA, there remain some unmet medical needs that require new treatment options. The objective of this work was to describe and apply a modeling and simulation approach to extrapolate upadacitinib efficacy from the adult diseases, rheumatoid arthritis (RA) and psoriatic arthritis (PsA), to their respective pediatric diseases, polyarticular course JIA (pcJIA), and juvenile PsA (JPsA).
View Article and Find Full Text PDFA Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a "Safety Checklist".
Drug Saf
November 2024
Department of Biomedicine, Aarhus University, Skou Building, Høegh-Guldbergs Gade 10, 8000, Aarhus C, Denmark.
Background/aim: The purpose of this review is to provide an overview of the contraindications, special warnings, and boxed warnings with the aim to establish a framework to create a prescription safety checklist for a class of drugs or disease indication. This study covers biologic disease modifying antirheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs).
Methods: We identified contraindications, boxed warnings, and special warnings provided by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!